Literature DB >> 24998845

A novel LKB1 isoform enhances AMPK metabolic activity and displays oncogenic properties.

R Dahmani1, P-A Just1, A Delay2, F Canal1, L Finzi1, C Prip-Buus3, M Lambert3, P Sujobert3, K Buchet-Poyau2, E Miller4, C Cavard1, S Marmier1, B Terris5, M Billaud2, C Perret1.   

Abstract

The LKB1 tumor suppressor gene encodes a master kinase that coordinates the regulation of energetic metabolism and cell polarity. We now report the identification of a novel isoform of LKB1 (named ΔN-LKB1) that is generated through alternative transcription and internal initiation of translation of the LKB1 mRNA. The ΔN-LKB1 protein lacks the N-terminal region and a portion of the kinase domain. Although ΔN-LKB1 is catalytically inactive, it potentiates the stimulating effect of LKB1 on the AMP-activated protein kinase (AMPK) metabolic sensor through a direct interaction with the regulatory autoinhibitory domain of AMPK. In contrast, ΔN-LKB1 negatively interferes with the LKB1 polarizing activity. Finally, combining in vitro and in vivo approaches, we showed that ΔN-LKB1 has an intrinsic oncogenic property. ΔN-LKB1 is expressed solely in the lung cancer cell line, NCI-H460. Silencing of ΔN-LKB1 decreased the survival of NCI-H460 cells and inhibited their tumorigenicity when engrafted in nude mice. In conclusion, we have identified a novel LKB1 isoform that enhances the LKB1-controlled AMPK metabolic activity but inhibits LKB1-induced polarizing activity. Both the LKB1 tumor suppressor gene and the oncogene ΔN-LKB1 are expressed from the same locus and this may account for some of the paradoxical effects of LKB1 during tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24998845     DOI: 10.1038/onc.2014.182

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.

Authors:  Lu Chen; Brienne E Engel; Eric A Welsh; Sean J Yoder; Stephen G Brantley; Dung-Tsa Chen; Amer A Beg; Chunxia Cao; Frederic J Kaye; Eric B Haura; Matthew B Schabath; W Douglas Cress
Journal:  J Thorac Oncol       Date:  2016-02-23       Impact factor: 15.609

2.  Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Erin Bange; Melina E Marmarelis; Wei-Ting Hwang; Yu-Xiao Yang; Jeffrey C Thompson; Jason Rosenbaum; Joshua M Bauml; Christine Ciunci; Evan W Alley; Roger B Cohen; Corey J Langer; Erica Carpenter; Charu Aggarwal
Journal:  JCO Precis Oncol       Date:  2019-05-10

3.  AMPK potentiation by LKB1 isoforms.

Authors:  Chantal Thibert; Christine Perret; Marc Billaud
Journal:  Oncotarget       Date:  2015-11-03

4.  Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.

Authors:  Nicolas Pécuchet; Pierre Laurent-Puig; Audrey Mansuet-Lupo; Antoine Legras; Marco Alifano; Karine Pallier; Audrey Didelot; Laure Gibault; Claire Danel; Pierre-Alexandre Just; Marc Riquet; Françoise Le Pimpec-Barthes; Diane Damotte; Elisabeth Fabre; Hélène Blons
Journal:  Oncotarget       Date:  2017-04-04

Review 5.  Role of STK11 in ALK-positive non-small cell lung cancer.

Authors:  Wen Zhou; Lu-Da Yan; Zhi-Qiong Yu; Na Li; Yong-Hua Yang; Meng Wang; Yuan-Yuan Chen; Meng-Xia Mao; Xiao-Chun Peng; Jun Cai
Journal:  Oncol Lett       Date:  2022-04-15       Impact factor: 2.967

6.  Berberine and cinnamaldehyde together prevent lung carcinogenesis.

Authors:  Mingjing Meng; Shengnan Geng; Zhenhua Du; Jingjing Yao; Yaqiu Zheng; Zibo Li; Zhenzhen Zhang; Jiahuan Li; Yongjian Duan; Gangjun Du
Journal:  Oncotarget       Date:  2017-08-07

7.  Upregulation of liver kinase B1 predicts poor prognosis in hepatocellular carcinoma.

Authors:  Xiaolong Tan; Zhibin Liao; Huifang Liang; Xiaoping Chen; Bixiang Zhang; Liang Chu
Journal:  Int J Oncol       Date:  2018-09-07       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.